KT

Serial Number 99170049
661

Registration Progress

Application Filed
May 5, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Non-Final Action Mailed
Due: Nov 05, 2025 0 days

Trademark Image

KT

Basic Information

Serial Number
99170049
Filing Date
May 5, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
661
Status Date
Oct 8, 2025
Application
Pending
Classes
005

Rights Holder

Kymera Therapeutics, Inc.

03
Address
500 North Beacon St.
4th Floor
Watertown, MA 02472

Ownership History

Kymera Therapeutics, Inc.

Original Applicant
03
Watertown, MA

Legal Representation

Attorney
Lisa M. Tittemore

USPTO Deadlines

Next Deadline
0 days remaining
Non-Final Action Mailed
Due Date
November 05, 2025
Extension Available
Until February 05, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

13 events
Date Code Type Description Documents
Oct 8, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 29, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 29, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 5, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 5, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 5, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 21, 2025 PMSG O PETITION TO DIRECTOR - MAKE SPECIAL - GRANTED Loading...
Jul 14, 2025 APET A ASSIGNED TO PETITION STAFF Loading...
Jun 16, 2025 TPMS I TEAS PETITION TO DIRECTOR-MAKE SPECIAL-RECEIVED Loading...
May 5, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
May 5, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 5, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Therapeutic agents, namely pharmaceutical preparations for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, bullous pemphigoid, chronic spontaneous urticaria, lupus, Sjogren's Syndrome, rheumatoid arthritis, inflammatory bowel disease, and dermatomyositis
First Use Anywhere: 20241000
First Use in Commerce: 20241000

Additional Information

Pseudo Mark
K T;KYMERA THERAPEUTICS

Classification

International Classes
005